| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥2000Kunit Units/mg
| Targets |
DNA
|
|---|---|
| ln Vitro |
Extracellular DNA, also called cell-free DNA, released from dying cells or activated immune cells can be recognized by the immune system as a danger signal causing or enhancing inflammation. The cleavage of extracellular DNA is crucial for limiting the inflammatory response and maintaining homeostasis. Deoxyribonucleases (DNases) as enzymes that degrade DNA are hypothesized to play a key role in this process as a determinant of the variable concentration of extracellular DNA. DNases are divided into two families-DNase I and DNase II, according to their biochemical and biological properties as well as the tissue-specific production. Studies have shown that low DNase activity is both, a biomarker and a pathogenic factor in systemic lupus erythematosus. Interventional experiments proved that administration of exogenous DNase has beneficial effects in inflammatory diseases. Recombinant human DNase reduces mucus viscosity in lungs and is used for the treatment of patients with cystic fibrosis. This review summarizes the currently available published data about DNases, their activity as a potential biomarker and methods used for their assessment. An overview of the experiments with systemic administration of DNase is also included. Whether low-plasma DNase activity is involved in the etiopathogenesis of diseases remains unknown and needs to be elucidated.[1]
|
| ln Vivo |
In addition to inhibiting liver metastasis, deoxyribonuclease (0.1 U; ip; once daily for 3 days) increases the duration of survival when combined with surgical resection of the main tumor mass[1].
|
| Animal Protocol |
Animal/Disease Models: Female BALB/cx DBA/2 mice with murine tumor L5178Y-ML cells subcutaneous (sc) injection[1]
Doses: 0.1 U per mouse Route of Administration: intravenous (iv) injection; 0.1 U; one time/day for three days Experimental Results: decreased liver weight from 2.26 to 1.55 g, affected the intensity of liver metastasis, decreased the numbers and sizes of metastatic and affected tumor cell arrest. Animal/Disease Models: Female BALB/cx DBA/2 mice with murine tumour and surgical removal of subcutaneous (sc) tumours[1] Doses: 0.1 U per mouse Route of Administration: intravenous (iv) injection; 0.1 U; one time/day for 3 days either before or after primary tumor removal Experimental Results: Dramatically prolongated survival after tumor cell inoculation compared to the untreated group. |
| References | |
| Additional Infomation |
Subcutaneous transplantation of L5178Y-ML cells from mice into the flanks of (BALB/cx DBA/2)F1 mice resulted in localized cell growth and spontaneous liver metastasis. Even with surgical resection of the primary tumor 5 or 7 days after tumor cell inoculation, all mice died within 18 days due to liver metastasis. Using this tumor metastasis model, we investigated whether serine proteases or deoxyribonuclease I (DNase I) affect metastasis. Systemic administration of α-chymotrypsin on days 3, 4, and 5, or days 5, 6, and 7 after tumor cell inoculation enhanced spontaneous liver metastasis of L5178Y-ML cells. This result is consistent with previous reports on hematogenous lung metastasis. Conversely, systemic administration of DNase I on days 3, 4, and 5, or days 5, 6, and 7 after tumor cell inoculation inhibited liver metastasis. Neither treatment affected the growth of the primary tumor. Scanning electron microscopy results suggest that DNase I may affect the retention of tumor cells in the hepatic microvessels. DNase I treatment can significantly prolong survival, but the effect is not ideal. Combining surgical resection of the primary tumor with DNase I treatment can achieve a more significant anti-metastatic effect, thereby more effectively prolonging survival. These results suggest that DNase I may be a potential therapeutic drug that can be used in combination with surgery to prevent clinical hematogenous metastasis. [2]
|
| Molecular Formula |
C12H22N4O6
|
|---|---|
| Molecular Weight |
318.32628
|
| CAS # |
9003-98-9
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
100 g/mL at 20 °C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 43.48 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 5 mg/mL (Infinity mM) in Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1414 mL | 15.7070 mL | 31.4139 mL | |
| 5 mM | 0.6283 mL | 3.1414 mL | 6.2828 mL | |
| 10 mM | 0.3141 mL | 1.5707 mL | 3.1414 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA